1-methyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrazole | 1607838-15-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-methyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrazole
• 英文别名: 1-methyl-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1H-Pyrazole；1-methyl-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyrazole
• CAS: 1607838-15-2
• 化学式: C₁₆H₂₁BN₂O₂
• 分子量: 284.166
• InChiKey: BJQRUJRFGXXKGL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.39
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  36.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-methyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrazole 在 sodium periodate 、 盐酸 作用下， 以 四氢呋喃 、 水 为溶剂， 以56.26 %的产率得到[4-(1-methylpyrazol-3-yl)phenyl]boronic acid
  参考文献：
  名称：

  [EN] PYRIDAZINONE DERIVATIVES USEFUL AS T CELL ACTIVATORS
  [FR] DÉRIVÉS DE PYRIDAZINONE UTILES EN TANT QU'ACTIVATEURS DE LYMPHOCYTES T

  摘要：

  Disclosed herein are oxime compounds having the structure of Formula (I'): or a pharmaceutically acceptable salt, solvate, hydrate, isomer, tautomer, racemate, or isotope thereof, wherein L1, L2, R1, R2, R3, R4, R7, n, and r are as defined herein. Pharmaceutical compositions comprising them, processes for preparing them and uses of them to treat or prevent diseases, disorders and conditions are also provided. The compounds are inhibitors of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ) and are useful in the treatment of diseases, disorders and conditions related to DGKα and / or DGKζ activity. In particular, the compounds are useful for treating viral infections and proliferative disorders, such as cancer.

  公开号：

  WO2023122778A1
• 作为产物：
  描述：

  1,4-亚苯基二硼酸, 频哪醇二酯 、 3-溴-1-甲基吡咯 在 potassium phosphate 、 [1,1’-bis(di-tert-butylphosphino)ferrocene]dichloropalladium(Il) 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 1.0h， 以26%的产率得到1-methyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrazole
  参考文献：
  名称：

  NOVEL NAPHTHYRIDINES AND ISOQUINOLINES AND THEIR USE AS CDK8/19 INHIBITORS

  摘要：

  本发明涉及萘啶和异喹啉化合物，以及由此组成的药物可接受的组合物，作为CDK8/19的抑制剂，用于治疗与CDK8/19相关疾病。

  公开号：

  US20160016951A1

文献信息

• [EN] 2-AMINOPYRIDINE COMPOUNDS<br/>[FR] COMPOSÉS DE 2-AMINOPYRIDINE
  申请人：MERCK PATENT GMBH

  公开号：WO2014063778A1

  公开（公告）日：2014-05-01

  The invention provides novel substituted 2-aminopyridine compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases such as cancer, inflammatory or degenerative diseases.

  这项发明提供了根据式(I)提供的新型取代的2-氨基吡啶化合物，其制备和用于治疗癌症、炎症或退行性疾病等增生性疾病。
• 2-AMINOPYRIDINE COMPOUNDS
  申请人：MERCK PATENT GMBH

  公开号：US20150353548A1

  公开（公告）日：2015-12-10

  The invention provides novel substituted 2-aminopyridine compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases such as cancer, inflammatory or degenerative diseases.

  本发明提供了根据式（I）的新型取代2-氨基吡啶化合物，其制备和用于治疗高增殖性疾病，如癌症、炎症或退行性疾病的用途。
• [EN] PYRIDYL PIPERIDINES<br/>[FR] PYRIDYL-PIPÉRIDINES
  申请人：MERCK PATENT GMBH

  公开号：WO2015144290A8

  公开（公告）日：2015-12-23
• Discovery of Potent, Orally Bioavailable, Small-Molecule Inhibitors of WNT Signaling from a Cell-Based Pathway Screen
  作者：Aurélie Mallinger、Simon Crumpler、Mark Pichowicz、Dennis Waalboer、Mark Stubbs、Olajumoke Adeniji-Popoola、Bozena Wood、Elizabeth Smith、Ching Thai、Alan T. Henley、Katrin Georgi、William Court、Steve Hobbs、Gary Box、Maria-Jesus Ortiz-Ruiz、Melanie Valenti、Alexis De Haven Brandon、Robert TePoele、Birgitta Leuthner、Paul Workman、Wynne Aherne、Oliver Poeschke、Trevor Dale、Dirk Wienke、Christina Esdar、Felix Rohdich、Florence Raynaud、Paul A. Clarke、Suzanne A. Eccles、Frank Stieber、Kai Schiemann、Julian Blagg

  DOI：10.1021/jm501436m

  日期：2015.2.26

  WNT signaling is frequently deregulated in malignancy, particularly in colon cancer, and plays a key role in the generation and maintenance of cancer stem cells. We report the discovery and optimization of a 3,4,5-trisubstituted pyridine 9 using a high-throughput cell-based reporter assay of WNT pathway activity. We demonstrate a twisted conformation about the pyridine-piperidine bond of 9 by small-molecule X-ray crystallography. Medicinal chemistry optimization to maintain this twisted conformation, cognisant of physicochemical properties likely to maintain good cell permeability, led to 74 (CCT251545), a potent small-molecule inhibitor of WNT signaling with good oral pharmacokinetics. We demonstrate inhibition of WNT pathway activity in a solid human tumor xenograft model with evidence for tumor growth inhibition following oral dosing. This work provides a successful example of hypothesis-driven medicinal chemistry optimization from a singleton hit against a cell-based pathway assay without knowledge of the biochemical target.